Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Benchtop Hematology Analyzer Enables Reduction of Manual Review Rates and Processes

By BiotechDaily International staff writers
Posted on 09 May 2013
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
A new benchtop hematology cellular analysis system provides laboratories with quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Building on its proven cellular analysis technology to further advance and optimize clinical diagnostic laboratories, Beckman Coulter Inc. (Pasadena, CA, USA) introduces the “UniCel DxH 600” Coulter cellular analysis system, a new benchtop hematology analyzer for mid- to high-volume laboratories. The hematology laboratory’s single most important step, and most time consuming, is the manual review. By reducing manual differential rates, the new analyzer frees labs to focus time on quickly and accurately reporting patient results, improving patient health, and reducing the overall cost of care.

With the same technology, user interface, and consumables as the UniCel DxH 800 Coulter analyzer, the UniCel DxH 600 brings superior standardization of results and process to the hematology laboratory, reducing personnel training and simplifying consumable inventory management. (To further enhance standardization, all new DxH 800 analyzers will be installed with the advanced software; and DxH 800 currently in use will be upgraded.)

The UniCel DxH 600 is equipped with robust software—recently cleared by the US Food and Drug Administration (FDA)—that provides new features, enhancements, and research-use parameters. This advanced software also saves time by allowing labs to partially release patient results manually or automatically via decision rules. It also offers users the ability to create and edit decision rules during instrument operation and offers predefined decision rules using Cell Population Data (for research use only; not for use in diagnostic procedures). Additional features include the ability to track workload by the day, hour, and test, as well as providing automatic notification of STAT samples that have not been processed or released within an expected time frame, helping users to report STAT results efficiently.

"This new hematology analyzer has the ability to transform the hematology lab with unparalleled efficiency, revolutionary scalability, and quality of results,” said John Blackwood, senior vice president, Product Management at Beckman Coulter Diagnostics; “The UniCel DxH 600 advances the technology that [...] will change how labs manage their cellular analysis process.”

Related Links:

Beckman Coulter


Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.